Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN

Oncology Letters

Volumn 4, Issue 6, 2012, Pages 1305-1308

  Leinung, Martin ^a   Daniel, Hirth ^a   Tahtali, Aykut ^a   Diensthuber, Marc ^a   Timo, Stöver ^a   Wagenblast, Jens ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; BI2536; Bortezomib; Growth inhibition; Squamous cell head and neck carcinoma cell lines (SCCHN)

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; BORTEZOMIB; RARITAN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DOSE ESCALATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION;

EID: 84867267640     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.927     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001.
3. Gibson MK and Forastiere AA: Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol 7: 565-574, 2006.
4. Specenier P and Vermorken JB: Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 11: 511-524, 2011.
5. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al: Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23: 3562-3567, 2005.
6. Burtness B, Goldwasser MA, Flood W, Mattar B and Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654, 2005.
7. Wagenblast J, Hambek M, Baghi M, Gstottner W, Strebhardt K, Ackermann H, et al: Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 134: 323-330, 2008.
8. Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstottner W, Ackermann H, et al: Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 135: 387-393, 2009.
9. Zhang PL, Pellitteri PK, Law A, Gilroy PA, Wood GC, Kennedy TL, et al: Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 18: 924-932, 2005.
10. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, et al: Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66: 8210-8218, 2006.
11. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
12. Schoffski P: Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14: 559-570, 2009.
13. Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, et al: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 46: 2206-2215, 2010.
14. Datta D, Banerjee P, Gasser M, Waaga-Gasser AM and Pal S: CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem 285: 36842-36848, 2010.
15. Ray RB, Raychoudhuri A, Steele R and Nerurkar P: Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 70: 1925-1931, 2010.
16. Lun M, Zhang PL, Pellitteri PK, Law A, Kennedy TL and Brown RE: Nuclear factor-κB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and validation in human cell lines using Velcade and siRNA/N molecular F-κB. Ann Clin Lab Sci 35: 251-258, 2005.
17. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428, 2001.
18. Fribley A, Zeng Q and Wang CY: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24: 9695-9704, 2004.
19. Li C, Li R, Grandis JR and Johnson DE: Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 7: 1647-1655, 2008.
20. Allen C, Saigal K, Nottingham L, Arun P, Chen Z and Van Waes C. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-κB subunits in head and neck cancer. Clin Cancer Res 14: 4175-4185, 2008.
21. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, et al: Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63: 1400-1412, 2005.
22. Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, et al: Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 17: 5755-5764, 2011.
23. Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, et al: Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther 8: 2211-2220, 2009.
24. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, et al: Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22: 115-119, 2004.
25. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22: 2108-2121, 2004.
26. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, et al: Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10: 6111-6118, 2004.